Produção Nacional
Avaliação do metabolismo da glicose em pacientes acromegálicos antes e após tratamento com octreotide LAR
2008; Editora da Universidade de São Paulo; Volume: 52; Issue: 1 Linguagem: Inglês
10.1590/s0004-27302008000100009
ISSN1677-9487
AutoresLívia L. Corrêa, Giselle Fernandes Taboada, Flávia R. van Haute, Alessandra Ferri Casini, Giovanna A. Balarini, Leonardo Vieira Neto, Ednildo A. Machado, Rosita Fontes, Cláudia C. de Andrade, Yolanda Schrank, Mônica R. Gadelha,
Tópico(s)Ophthalmology and Eye Disorders
ResumoTo evaluate the glucose metabolism in acromegalic patients before and after treatment with octreotide LAR.This was a prospective and longitudinal study involving 30 patients from the acromegaly research outpatient clinic of the Endocrinology unit of the HUCFF/UFRJ. They underwent clinical and laboratorial evaluations, with measurements of growth hormone (GH), insulin-like growth factor type I (IGF-I), insulin, proinsulin, C peptide, glycosylated hemoglobin (HbA1c), IGF binding protein type 1 (IGFBP-1) and glucose, during oral glucose tolerance test (OGTT), before and after six months of treatment with octreotide LAR. The Wilcoxon signed-rank test was used and values of 5% were considered statistically significant.We found 16 (54%) patients with normal glucose tolerance, 7 (23%) with impaired glucose tolerance and 7 (23%) diabetics. Twelve patients completed the six-month treatment, out of which three showed worsening of glucose tolerance and two (diabetics) had worse blood glucose control. Whereas there was an increase in waist circumference (p=0.03), there was a decrease in GH (p=0.04), with %IGF-I above the upper limit of reference values (% ULRV) [p=0.001], insulin (p=0.019), C peptide levels (p=0.002) and homeostatic model assessment (HOMA-IR) [p=0.039].In this series, treatment with octreotide LAR led to a worsening of glucose tolerance in three non-diabetic patients and worsened glycemic control in two diabetics, in spite of reducing insulin resistance.
Referência(s)